Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENLV NASDAQ:NEUP NASDAQ:RLYB NASDAQ:TNFA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENLVEnlivex Therapeutics$1.07$1.24$0.81▼$2.10$25.31M0.831.12 million shs213,937 shsNEUPNeuphoria Therapeutics$13.01-7.0%$8.98$2.12▼$15.14$26.30M0.5774,030 shs63,866 shsRLYBRallybio$0.60+1.6%$0.53$0.22▼$1.24$24.72M-1.1381,762 shs99,112 shsTNFATNF Pharmaceuticals$3.89-3.7%$9.12$3.24▼$195.00$7.46M2.04871,606 shs236,724 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENLVEnlivex Therapeutics0.00%+0.94%-31.41%+18.23%-17.69%NEUPNeuphoria Therapeutics-7.01%+9.42%+63.65%+90.76%+1,300,999,900.00%RLYBRallybio+1.56%-1.28%+12.22%+85.43%-45.87%TNFATNF Pharmaceuticals-3.71%+17.88%-62.95%-71.61%-97.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENLVEnlivex Therapeutics$1.07$1.24$0.81▼$2.10$25.31M0.831.12 million shs213,937 shsNEUPNeuphoria Therapeutics$13.01-7.0%$8.98$2.12▼$15.14$26.30M0.5774,030 shs63,866 shsRLYBRallybio$0.60+1.6%$0.53$0.22▼$1.24$24.72M-1.1381,762 shs99,112 shsTNFATNF Pharmaceuticals$3.89-3.7%$9.12$3.24▼$195.00$7.46M2.04871,606 shs236,724 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENLVEnlivex Therapeutics0.00%+0.94%-31.41%+18.23%-17.69%NEUPNeuphoria Therapeutics-7.01%+9.42%+63.65%+90.76%+1,300,999,900.00%RLYBRallybio+1.56%-1.28%+12.22%+85.43%-45.87%TNFATNF Pharmaceuticals-3.71%+17.88%-62.95%-71.61%-97.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENLVEnlivex Therapeutics 3.00Buy$10.00834.58% UpsideNEUPNeuphoria Therapeutics 3.00Buy$28.00115.22% UpsideRLYBRallybio 2.00Hold$5.00732.22% UpsideTNFATNF Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TNFA, ENLV, RLYB, and NEUP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.009/11/2025NEUPNeuphoria TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $35.009/2/2025ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.008/26/2025NEUPNeuphoria TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.008/18/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.007/29/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.007/22/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.00 per shareN/ANEUPNeuphoria Therapeutics$10K2,445.88N/AN/A$15.85 per share0.82RLYBRallybio$640K39.23N/AN/A$1.49 per share0.40TNFATNF PharmaceuticalsN/AN/AN/AN/A$286.76 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENLVEnlivex Therapeutics-$15.01M-$0.58N/AN/AN/AN/A-58.31%-50.32%N/ANEUPNeuphoria Therapeutics-$15.49MN/A0.00N/AN/AN/AN/AN/A9/29/2025 (Estimated)RLYBRallybio-$57.78M-$0.94N/AN/AN/A-5,473.33%-71.66%-65.06%11/6/2025 (Estimated)TNFATNF Pharmaceuticals-$23.36M-$231.00N/A∞N/AN/A-69.21%-33.98%11/12/2025 (Estimated)Latest TNFA, ENLV, RLYB, and NEUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/29/2025N/ANEUPNeuphoria Therapeutics-$1.26N/AN/AN/AN/AN/A8/19/2025Q2 2025TNFATNF PharmaceuticalsN/A-$18.00N/A-$0.18N/AN/A8/7/2025Q2 2025RLYBRallybio-$0.2450-$0.22+$0.0250-$0.22N/A$0.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENLVEnlivex TherapeuticsN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENLVEnlivex TherapeuticsN/A6.416.41NEUPNeuphoria TherapeuticsN/A11.0111.01RLYBRallybioN/A9.989.98TNFATNF PharmaceuticalsN/A0.930.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENLVEnlivex Therapeutics1.02%NEUPNeuphoria Therapeutics15.90%RLYBRallybio90.34%TNFATNF Pharmaceuticals9.64%Insider OwnershipCompanyInsider OwnershipENLVEnlivex Therapeutics12.28%NEUPNeuphoria Therapeutics0.69%RLYBRallybio8.70%TNFATNF Pharmaceuticals0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENLVEnlivex Therapeutics7023.65 million20.75 millionOptionableNEUPNeuphoria TherapeuticsN/A1.88 million1.87 millionN/ARLYBRallybio4041.79 million38.15 millionNot OptionableTNFATNF Pharmaceuticals61.85 million1.78 millionN/ATNFA, ENLV, RLYB, and NEUP HeadlinesRecent News About These CompaniesTNF Pharmaceuticals (NASDAQ:TNFA) Stock Rating Upgraded by Wall Street ZenSeptember 7, 2025 | americanbankingnews.comTNF Pharmaceuticals (NASDAQ:TNFA) Sees Large Volume Increase - What's Next?September 5, 2025 | marketbeat.comTNF Pharmaceuticals (NASDAQ:TNFA) Hits New 12-Month Low - Should You Sell?September 4, 2025 | marketbeat.comTNF Pharmaceuticals Announces Closing of $7 Million Private PlacementSeptember 4, 2025 | businesswire.comTNF Pharmaceuticals stock climbs after securing exclusive crypto computing rightsSeptember 2, 2025 | investing.comPharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency ApplicationsSeptember 2, 2025 | businesswire.comTNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing ComplianceAugust 29, 2025 | finance.yahoo.comTNF Pharmaceuticals announces improved financial positionAugust 20, 2025 | msn.comTNF Pharmaceuticals Strengthens Financial Position for Growth and Value CreationAugust 19, 2025 | businesswire.comTNF Pharmaceuticals Inc Ordinary Shares TNFA - MorningstarJuly 11, 2025 | morningstar.comMAkers files written objection to her Judicial Investigative admonishmentJuly 4, 2025 | wvgazettemail.comWDorothy Marillyn AkersJuly 2, 2025 | chattanoogan.comCNewly-signed running back Cam Akers has already changed his jersey numberJune 30, 2025 | msn.comTNF Pharmaceuticals, Inc. (TNFA) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comAdmonishing Akers, Sweeney Wrong; Will Make Matters WorseJune 26, 2025 | wvmetronews.comWTNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory DiseaseJune 25, 2025 | finance.yahoo.comClinton native Cam Akers signs with New Orleans SaintsJune 17, 2025 | msn.comSaints' Cam Akers: Gets chance with SaintsJune 15, 2025 | cbssports.comFormer Houston Texans RB Cam Akers signs one-year deal with the SaintsJune 14, 2025 | msn.comCam Akers, Saints Reportedly Agree to Contract in Free Agency, Updated Depth ChartJune 14, 2025 | bleacherreport.comBReport: Saints sign Akers after tryoutJune 14, 2025 | thescore.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNFA, ENLV, RLYB, and NEUP Company DescriptionsEnlivex Therapeutics NASDAQ:ENLV$1.07 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.08 +0.01 (+0.93%) As of 09/12/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Neuphoria Therapeutics NASDAQ:NEUP$13.01 -0.98 (-7.01%) As of 09/12/2025 04:00 PM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.Rallybio NASDAQ:RLYB$0.60 +0.01 (+1.56%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.59 -0.01 (-1.30%) As of 09/12/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.TNF Pharmaceuticals NASDAQ:TNFA$3.89 -0.15 (-3.71%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.90 +0.00 (+0.13%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
